Analysts’ Viewpoint
Continuous research & development, increase in prevalence of cardiovascular diseases (CVDs), and development of new combination therapies and precision medicine approaches are driving the global RAS-acting agents market. Increase in investment by pharmaceutical companies in research & development, particularly in the area of CVDs, are expected to propel market expansion.
Combination therapies that target multiple aspects of the renin-angiotensin system (RAS) are gaining popularity, as these can be more effective than single-agent therapies. Manufacturers primarily focus on the development of new combination therapies in order to increase market share and presence.
The renin-angiotensin system (RAS) is a complex hormonal system that helps regulate blood pressure and fluid balance in the body. RAS-acting agents/drugs target different components of this system and are used to treat various cardiovascular and renal disorders. The action of ACE enzymes, which convert angiotensin I to angiotensin II, is blocked by angiotensin-converting enzyme (ACE) inhibitors. Angiotensin II is a potent vasoconstrictor that can raise blood pressure. ACE inhibitors, such as lisinopril, enalapril, and captopril, lower blood pressure by reducing the production of angiotensin II.
RAS-acting agents significantly impact cardiovascular and renal health and are used to manage various conditions related to high blood pressure and heart failure. However, these could also cause side effects such as hypotension, cough, and hyperkalemia. Hence, they should be used under the guidance of a healthcare professional.
The increase in the prevalence of CVDs is one of the key drivers of global business. According to the World Health Organization (WHO), CVD is the leading cause of death worldwide, accounting for nearly 17.9 million deaths each year.
RAS-acting agents are commonly used to treat hypertension and heart failure, both of which are major risk factors for CVDs. An increase in the incidence of these conditions drives demand for RAS-acting agents. Additionally, ongoing research into the potential use of RAS-acting agents for other conditions, such as kidney disease, is expected to augment the RAS-acting agents market forecast.
The surge in the availability of generic versions of these drugs is propelling the market. This is making treatment more affordable for patients and expanding their access to health care. However, the market faces challenges such as competition from alternative treatments and potential side effects associated with RAS-acting agents.
The RAS is a complex hormonal system, which plays a critical role in regulating blood pressure and fluid balance in the body. Ongoing RAS-acting agents market research into the many components of the system and its potential therapeutic targets leads to market expansion.
New drugs that target different components of RAS are being developed and tested, including agents that target renin, ACE, angiotensin II receptors, and other key proteins in the system. Additionally, continuous research into the use of RAS-acting agents for the treatment of other conditions, such as kidney disease and pulmonary hypertension, augment the market.
A rise in interest in the development of combination therapies, which target multiple components of RAS simultaneously, with the goal of achieving more effective blood pressure control and improved outcomes, also propels the market. For example, combination therapies that include both an ACE inhibitor and an angiotensin II receptor blocker (ARB) have been shown to be effective in some patients with hypertension. These factors are fueling global RAS-acting agents industry growth.
In terms of drug class, the ACE inhibitors segment accounted for the leading global RAS-acting agents market share in 2022. ACE inhibitors are widely prescribed for the treatment of hypertension and heart failure. These drugs work by blocking the action of ACE, an enzyme that converts angiotensin I to angiotensin II and is a potent vasoconstrictor, which can raise blood pressure.
ACE inhibitors are recommended as first-line therapy in several major clinical guidelines for the treatment of hypertension and heart failure, further contributing to their widespread usage and market dominance. Lisinopril, enalapril, and ramipril.
ACE inhibitors have been used for several decades, and are considered a standard of care for several patients with hypertension and heart failure. These have a well-established safety and efficacy profile and are available in both generic and branded formulations.
Based on indication, the hypertension segment dominated the global market in 2022. Hypertension, or high blood pressure, is a common condition that affects a large number of people across the world and is a major risk factor for a range of CVDs, including stroke, heart attack, and heart failure.
RAS-acting agents, particularly ACE inhibitors and ARBs, are widely used for the treatment of hypertension. These drugs work by reducing the activity of RAS, thereby lowering blood pressure and reducing the risk of cardiovascular complications. Additionally, RAS-acting agents are often used in combination with other classes of antihypertensive drugs, such as diuretics or calcium channel blockers, to achieve optimal blood pressure control.
The hypertension indication segment is expected to continue to grow in the next few years owing to a surge in the prevalence of hypertension, the availability of new and improved RAS-acting agents, and an increase in focus on combination therapies for hypertension management.
In terms of distribution channels, the hospital pharmacies segment accounted for a significant share of the global RAS-action agents market in 2022. Hospital pharmacies are an important distribution channel for RAS-acting agents, particularly for patients with hypertension, heart failure, and other CVDs who are hospitalized or receiving treatment in an inpatient setting.
Hospital pharmacies often have access to a range of RAS-acting agents, including newer and more specialized drugs that may not be available in retail pharmacies. This can be particularly important for patients with complex medical conditions who require tailored treatment regimens.
Hospital pharmacies are also often responsible for the administration of RAS-acting agents in a hospital or clinical setting, through intravenous infusion or injection. This can require specialized expertise and equipment, which may not be available in other types of pharmacies.
North America accounted for a major share of the global RAS-acting agents market in 2022. This can be attributed to the high prevalence of CVDs, such as hypertension and heart failure, in the region, the availability of advanced healthcare infrastructure and facilities, and the presence of several key market players.
North America also has a strong regulatory environment and well-established healthcare system, which can facilitate the development and commercialization of new RAS-acting agents. High levels of research & development activities are undertaken in the pharmaceutical industry in the region, which can lead to the discovery and development of new drugs targeting the RAS.
Product portfolio expansion and mergers & acquisitions are key strategies adopted by key manufacturers in the global RAS-acting agents market. Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, and Johnson & Johnson are the prominent players in the market.
The RAS-acting agents market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent market developments.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 9.7 Bn |
|
Forecast (Value) in 2031 |
More than US$ 13.4 Bn |
|
Growth Rate (CAGR) |
4.2% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 9.7 Bn in 2022.
It is projected to reach more than US$ 13.4 Bn by 2031.
The business is anticipated to grow at a CAGR of 4.2% from 2023 to 2031.
Increase in prevalence of CVDs globally and continuous research and development are the prominent players in the market.
North America is estimated to be a prominent region during the forecast period.
Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, and Johnson & Johnson are the prominent players in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global RAS-acting Agents Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global RAS-acting Agents Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. Key Industry Events
5.4. COVID-19 Impact Analysis
6. Global RAS-acting Agents Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. ACE inhibitors
6.3.2. Angiotensin II Receptor Blockers (ARBs)
6.3.3. Renin Inhibitors
6.3.4. Aldosterone Antagonists
6.3.5. Others (diuretics)
6.4. Market Attractiveness Analysis, by Drug Class
7. Global RAS-acting Agents Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Hypertension
7.3.2. Heart Failure
7.3.3. Chronic Kidney Disease
7.3.4. Diabetic Nephropathy
7.3.5. Coronary Artery Disease
7.4. Market Attractiveness Analysis, by Indication
8. Global RAS-acting Agents Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global RAS-acting Agents Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America RAS-acting Agents Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. ACE inhibitors
10.2.2. Angiotensin II Receptor Blockers (ARBs)
10.2.3. Renin Inhibitors
10.2.4. Aldosterone Antagonists
10.2.5. Others (diuretics)
10.3. Market Value Forecast, by Indication, 2017–2031
10.3.1. Hypertension
10.3.2. Heart Failure
10.3.3. Chronic Kidney Disease
10.3.4. Diabetic Nephropathy
10.3.5. Coronary Artery Disease
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe RAS-acting Agents Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. ACE inhibitors
11.2.2. Angiotensin II Receptor Blockers (ARBs)
11.2.3. Renin Inhibitors
11.2.4. Aldosterone Antagonists
11.2.5. Others (diuretics)
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. Hypertension
11.3.2. Heart Failure
11.3.3. Chronic Kidney Disease
11.3.4. Diabetic Nephropathy
11.3.5. Coronary Artery Disease
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific RAS-acting Agents Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. ACE inhibitors
12.2.2. Angiotensin II Receptor Blockers (ARBs)
12.2.3. Renin Inhibitors
12.2.4. Aldosterone Antagonists
12.2.5. Others (diuretics)
12.3. Market Value Forecast, by Indication, 2017–2031
12.3.1. Hypertension
12.3.2. Heart Failure
12.3.3. Chronic Kidney Disease
12.3.4. Diabetic Nephropathy
12.3.5. Coronary Artery Disease
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America (LATAM) RAS-acting Agents Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. ACE inhibitors
13.2.2. Angiotensin II Receptor Blockers (ARBs)
13.2.3. Renin Inhibitors
13.2.4. Aldosterone Antagonists
13.2.5. Others (diuretics)
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. Hypertension
13.3.2. Heart Failure
13.3.3. Chronic Kidney Disease
13.3.4. Diabetic Nephropathy
13.3.5. Coronary Artery Disease
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of LATAM
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa RAS-acting Agents Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. ACE inhibitors
14.2.2. Angiotensin II Receptor Blockers (ARBs)
14.2.3. Renin Inhibitors
14.2.4. Aldosterone Antagonists
14.2.5. Others (diuretics)
14.3. Market Value Forecast, by Indication, 2017–2031
14.3.1. Hypertension
14.3.2. Heart Failure
14.3.3. Chronic Kidney Disease
14.3.4. Diabetic Nephropathy
14.3.5. Coronary Artery Disease
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Drug Class Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer, Inc.
15.3.2.1. Company Overview
15.3.2.2. Drug Class Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. AstraZeneca plc
15.3.3.1. Company Overview
15.3.3.2. Drug Class Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Drug Class Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Sanofi S.A.
15.3.5.1. Company Overview
15.3.5.2. Drug Class Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bristol-Myers Squibb Company
15.3.6.1. Company Overview
15.3.6.2. Drug Class Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Daiichi Sankyo Company, Limited
15.3.7.1. Company Overview
15.3.7.2. Drug Class Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Takeda Pharmaceutical Company Limited
15.3.8.1. Company Overview
15.3.8.2. Drug Class Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Boehringer Ingelheim GmbH
15.3.9.1. Company Overview
15.3.9.2. Drug Class Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Johnson & Johnson
15.3.10.1. Company Overview
15.3.10.2. Drug Class Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 03: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 07: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 11: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 16: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 24: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global RAS-acting Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global RAS-acting Agents Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global RAS-acting Agents Market Value Share, by Drug Class, 2022
Figure 04: Global RAS-acting Agents Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global RAS-acting Agents Market Value Share, by Indication, 2022
Figure 06: Global RAS-acting Agents Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global RAS-acting Agents Market Value Share, by Distribution Channel, 2022
Figure 08: Global RAS-acting Agents Market Value Share, by Region, 2022
Figure 09: Global RAS-acting Agents Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 11: Global RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 12: Global RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 13: Global RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
Figure 14: Global RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 15: Global RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global RAS-acting Agents Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global RAS-acting Agents Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America RAS-acting Agents Market Attractiveness Analysis, by Country, 2017–2031
Figure 20: North America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: North America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 22: North America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 23: North America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 24: North America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 25: North America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 26: North America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 27: Europe RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Europe RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 31: Europe RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 32: Europe RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Europe RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 34: Europe RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 35: Europe RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 38: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 40: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 41: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 43: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 44: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 47: Latin America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 49: Latin America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 50: Latin America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Latin America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 52: Latin America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 53: Latin America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 56: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 58: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 59: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 61: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 62: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
RAS-acting Agents Market
*86 figures and 60 tables includes